Streetbeat News

Stock Prices

AUUD

Auddia announced the pricing of a 4.735 million share registered direct offering at $0.65 per share, leading to its shares trading lower on an abnormally-high volume.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 4:16 pm

DOOO

DA Davidson upgraded BRP's stock from Neutral to Buy, leading to an increase in share prices.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 4:15 pm

VUZI

Vuzix Corporation (NASDAQ:VUZI) has received a follow-on OEM purchase order for engineering services and products from a major U.S.-based defense customer. The order is for Phase 2 development of components for a lightweight heads-up display (HUD) and brings the total contract value closer to a mid-six-figure level.

Portfolio Pulse from Shivani Kumaresan

June 13, 2023 | 4:14 pm

EDIT

Raymond James upgraded Editas Medicine (EDIT) from Market Perform to Outperform and set a $17 price target, causing the stock to trade higher.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 4:14 pm

ETNB

89bio shares are trading higher after Evercore ISI Group initiated coverage on the stock with an Outperform rating and a $49 price target.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 4:13 pm

AI

C3.ai shares are experiencing an increase in value due to the ongoing positive momentum in AI stocks.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 4:05 pm

CCL

CUK

Carnival shares are trading higher amid strength in cruise stocks, and the stock received multiple analyst upgrades on Monday.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 4:04 pm

NTLA

Over the past 3 months, 10 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock, with 2 bullish, 7 somewhat bullish, and 1 indifferent. The company has an average 12-month price target of $74.4, down 6.84% from the previous average of $79.86.

Portfolio Pulse from Benzinga Insights

June 13, 2023 | 4:04 pm

TRI

Thomson Reuters (NYSE:TRI) has outperformed the market over the past 5 years, producing an average annual return of 22.6%. A $1000 investment in TRI 5 years ago would be worth $2,762.40 today.

Portfolio Pulse from Benzinga Insights

June 13, 2023 | 4:04 pm

OCUL

Ocular Therapeutix (NASDAQ:OCUL) has received 2 bullish and 3 somewhat bullish ratings from analysts in the last quarter. The average 12-month price target for the stock is $12.8, up 19.96% from the previous average of $10.67.

Portfolio Pulse from Benzinga Insights

June 13, 2023 | 4:03 pm